Literature DB >> 15251115

Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL.

Syunji Mizunoe1, Jun-Ichi Kadota, Issei Tokimatsu, Kenji Kishi, Hiroyuki Nagai, Masaru Nasu.   

Abstract

To evaluate the anti-inflammatory action of macrolide antibiotics, we examined whether macrolide antibiotics could induce apoptosis of activated lymphocytes. The proportion of apoptotic cells was augmented by clarithromycin (CLR) and azithromycin (AZM) compared with control. There was no significant difference in Fas and Fas-ligand expression between the control and macrolide-treated groups. CLR and AZM inhibited the expression of Bcl-xL compared with that of control. Our results suggest that CLR and AZM enhance apoptosis of activated lymphocytes by down-regulation of Bcl-xL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15251115     DOI: 10.1016/j.intimp.2004.05.011

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  18 in total

1.  A case of follicular B-cell lymphoma treated using clarithromycin.

Authors:  Masashi Ohe; Satoshi Hashino
Journal:  Korean J Hematol       Date:  2011-09-30

Review 2.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

3.  Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model.

Authors:  Nagwa I Abdel-Hamid; Mona F El-Azab; Yasser M Moustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-09       Impact factor: 3.000

4.  Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease.

Authors:  Christian Gluud; Bodil Als-Nielsen; Morten Damgaard; Jørgen Fischer Hansen; Stig Hansen; Olav H Helø; Per Hildebrandt; Jørgen Hilden; Gorm Boje Jensen; Jens Kastrup; Hans Jørn Kolmos; Erik Kjøller; Inga Lind; Henrik Nielsen; Lars Petersen; Christian M Jespersen
Journal:  Cardiology       Date:  2008-05-02       Impact factor: 1.869

5.  Azithromycin effectiveness against intracellular infections of Francisella.

Authors:  Saira Ahmad; Lyman Hunter; Aiping Qin; Barbara J Mann; Monique L van Hoek
Journal:  BMC Microbiol       Date:  2010-04-23       Impact factor: 3.605

Review 6.  Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Authors:  Helen C Steel; Annette J Theron; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2012-06-21       Impact factor: 4.711

7.  Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Authors:  An Mt Van Nuffel; Vidula Sukhatme; Pan Pantziarka; Lydie Meheus; Vikas P Sukhatme; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2015-02-24

8.  Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.

Authors:  F Ratzinger; H Haslacher; W Poeppl; G Hoermann; J J Kovarik; S Jutz; P Steinberger; H Burgmann; W F Pickl; K G Schmetterer
Journal:  Sci Rep       Date:  2014-12-11       Impact factor: 4.379

9.  First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Sung-Hsin Kuo; Kun-Huei Yeh; Ming-Shiang Wu; Chung-Wu Lin; Ming-Feng Wei; Jyh-Ming Liou; Hsiu-Po Wang; Li-Tzong Chen; Ann-Lii Cheng
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

10.  Azithromycin synergistically enhances anti-proliferative activity of vincristine in cervical and gastric cancer cells.

Authors:  Xuezhang Zhou; Yuyan Zhang; Yong Li; Xiujing Hao; Xiaoming Liu; Yujiong Wang
Journal:  Cancers (Basel)       Date:  2012-12-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.